- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and ...

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation ...

Concise regulatory statusPivotal trialOveporextonTakedaNarcolepsy (orexin‑2 agonist)US, EU, JPPhase III completed; filings ...

Major regulatory overhaul in the EUThe European Union’s lawmakers have agreed a provisional pharma package to modernise ...

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior ...

Antin Infrastructure Partners (Paris:ANTIN) has agreed to acquire NorthC Datacenters, a leading enterprise colocation data ...

Funding will further scale the company’s multimodal ML platform for patient selectionSAN FRANCISCO--(BUSINESS ...

Accenture (NYSE: ACN) has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and ...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into ...

Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ...

Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement ...